Chugai Pharmaceutical - Company History

Updated: Author:

Financial history 1957–2025 — revenue, cost structure, balance sheet, cash flow and key ratios, year by year →

Founded 1925
Founder Ueno Juzo
Founding location 東京都
Core business at founding Import agency for the medicines of Gehe of Germany
Listed 1956
President Okuda Osamu President since 2020 (age 63, as of 2026)
Current priority R&D · AI adoption Concentrating drug discovery at Yokohama, and mid-size molecules and AI-driven discovery
Founding
In March 1925 Ueno Juzo founded Chugai Shinyaku Shokai in Tokyo as a sole proprietorship. After the Great Kanto Earthquake, Ueno, then working at a trading company, judged that demand for medicines would last, and he began as an import agent for Gehe of Germany — a way into the market that needed no plant of his own. In 1927 he built a factory at Ikebukuro and moved on to manufacturing the injectable Zarsobrocanon, turning an import agency into a manufacturer. Ueno said he would go all-in on Zarublo, and went on running the company by raising the efficiency with which it made and sold what it already had rather than by adding product lines. In 1943 the firm was reorganised as a joint-stock company, and in 1951 it launched the detoxicant Guronsan, built on the glucuronic acid research of Professor Ishidate Morizo of the University of Tokyo. Moving into manufacturing without a research laboratory of its own is the starting point that set the task for the next generation.
The Decision
It gave away a majority of its capital and kept only drug discovery and early development in its own hands. The missed dividend of the year to March 1966 and the 420 early retirements showed the limit of a business run on turning other people’s academic results into products. From the mid-1970s research began on the recombinant biologic Neutrogin, with no date on which it would pay; it reached the market in 1991, more than a decade after the work started. In 1987, in the middle of that stretch, Amgen of the United States sued over the EPO patents, and it became plain that a mid-sized Japanese firm could carry neither the tens of billions of yen a single product costs in late-stage clinical trials nor an overseas sales network. In December 2001 Chugai signed a basic agreement on a strategic alliance with Roche of Switzerland and handed over a majority of its shares; by the end of March 2003 Roche’s holding stood at 50.13 per cent. That division of labour — late-stage development and overseas selling given to the other side, in exchange for terms that preserved the listing and the independence of its own discovery — is what produces the company’s margin today.
Today
Close to half of revenue drops straight through to operating profit. Against revenue of $8.4B (¥1.26tn) in the year to December 2025, operating profit was $4.0B (¥598bn) and net profit $2.9B (¥434bn), an operating margin of 47.6 per cent. Because Roche carries the late-stage trials and the selling abroad, selling, general and administrative expenses came to $778.5M (¥117bn), less than a tenth of revenue. On the product side, Actemra, the first antibody drug created in Japan, launched in 2005, has been followed by emicizumab for haemophilia A, also discovered in-house. On the research side the company closed its two sites at Fuji-Gotemba and Kamakura in March 2023 and concentrated everything at Chugai Life Science Park Yokohama, which began operating that April. A division of labour under which it does only discovery and early development is what lets 7,872 consolidated employees stand up revenue of more than a trillion yen.
Competition
The drugs it creates sell worldwide, but it is the parent that chooses who they are sold to. To the same question — how a mid-sized domestic firm is to get hold of an overseas sales network — its peers gave different answers. Daiichi Sankyo split profit and cost with AstraZeneca product by product while keeping control of the company in its own hands. Shionogi holds shares in ViiV Healthcare of the United Kingdom and takes royalties on HIV drugs, which is a way of handing the selling itself to someone else. Chugai sits between the two: in exchange for a majority of its shares it obtained exclusive rights to sell Roche’s products in Japan. The constraint of capital scale that the EPO patent suit of 1987 laid bare is resolved by that. The point of competition is neither the domestic sales floor nor the drug price, but whether the laboratory at Yokohama can go on producing drugs that Roche wants to sell around the world.

Timeline

1923–1971<q>All-in on Zarublo</q>: the single-product dependence it built

  1. 1925Chugai Shinyaku Shokai founded as a sole proprietorship in March
  2. 1927Ikebukuro factory opens; manufacture of medicines begins
  3. 1943Reorganised as a joint-stock company and renamed Chugai Pharmaceutical
  4. 1944Matsunaga Seiyakusho absorbed; the Matsunaga plant established
  5. 1950Patent rights to the glucuronic acid work acquired
  6. 1951The detoxicant Guronsan launched as an injectable
  7. 1954Synthesis from starch and dilute nitric acid established
  8. 1956Shares listed on the Tokyo Stock Exchange
  9. 1960Central Research Laboratory established
  10. 1964The Chugai-kai pharmacy-channel scheme launched
  11. 1966Dividend missed; 420 voluntary early retirements sought
  12. 1971Entry into clinical diagnostics

1972–2001Twenty years staked on biotechnology that could not be dated

  1. 1984Equity stake in Genetics Institute; EPO manufacturing and marketing rights acquired
  2. 1987Amgen sues over the EPO patents; the dispute begins
  3. 1987Fuji-Gotemba Research Laboratories established
  4. 1987Clinical trials of Neutrogin begin
  5. 1989Gen-Probe of the United States acquired, taking Chugai into DNA diagnostics
  6. 1990Joint venture with Rhône-Poulenc: Chugai Rhône-Poulenc established
  7. 1990Utsunomiya plant established
  8. 1991The biologic Neutrogin launched
  9. 1992Nagayama Osamu becomes president and representative director
  10. 1993Chugai Pharma UK established
  11. 1995United States subsidiary established
  12. 2001Tsukuba Research Laboratories opened
  13. 2001Basic agreement on a strategic alliance signed with Roche in December

2002–2026A majority entrusted to Roche to keep discovery independent

  1. 2002Gen-Probe spun off in September
  2. 2002Merger with Nippon Roche in October; Roche takes about 50.1 per cent of the shares
  3. 2003Roche’s holding stands at 50.13 per cent at the end of March
  4. 2003Takada Research Laboratories and the Matsunaga plant closed
  5. 2004The over-the-counter medicines business transferred to Lion
  6. 2005Actemra, the first antibody drug created in Japan, launched
  7. 2005Kagamiishi plant and Tohoku Chugai Pharmaceutical transferred to Nipro
  8. 2010Chugai Pharma Manufacturing’s Kamakura plant closed
  9. 2012Research subsidiary established in Singapore
  10. 2014Nikken Chugai Pharma established in China
  11. 2015Overseas subsidiaries reorganised
  12. 2015Hemlibra (emicizumab) launched for haemophilia A
  13. 2022Development and sales functions in China integrated
  14. 2023Fuji-Gotemba and Kamakura Research Laboratories closed
  15. 2023Chugai Life Science Park Yokohama begins operating

Founding Story

1923–1971<q>All-in on Zarublo</q>: the single-product dependence it built

For its first half-century Chugai carried one product at a time — an imported line, then an injectable, then the detoxicant Guronsan — and each time the whole company rose and fell with it. Sales grew from $7.6M (¥3bn) in 1957 to $56.7M (¥20bn) in 1971, but the same concentration that produced the growth also produced the missed dividend of March 1966, and it was that year, rather than any of the good ones, that pushed Chugai towards research of its own.

From import agent into the manufacture of injectables

After the Great Kanto Earthquake of 1923, Ueno Juzo (上野十蔵)[1], then working at a trading company, judged that demand for medicines would be durable, and in March 1925 he founded Chugai Shinyaku Shokai as a sole proprietorship[2]. He began as an import agent for the German firm Gehe, a way of entering the market that required no manufacturing plant of his own. In 1927 he built a factory at Ikebukuro and began making the prescription injectable Zarsobrocanon (ザルソブロカノン)[3], completing the turn from import agency into manufacturing. Ueno described his own method as all-in on Zarublo[4]: he concentrated the firm’s resources on a single product and went on choosing greater efficiency in making and selling what he already had over diversification. The risk that the Gehe import contract might one day be cut off, and the choice to invest in only a few products, together fixed the shape of prewar Chugai.

In 1936 the company added the Takada plant and enlarged its production scale, and in 1943 it was reorganised as a joint-stock company[5], giving it a base from which to raise capital. Prewar Chugai kept its research and development spending limited, running the business instead on concentrated investment in a small number of products and on the steady accumulation of supply capacity. Ueno himself acknowledged what the constraint on research capability and people meant for the range of products he could offer, recalling that the medicines we cannot write are the ones for the heart and the liver.[6] A business model that was an extension of import agency carried a structural weakness: it moved into manufacturing without ever building a research base of its own. After the war, when Ueno said that Japan’s recovery needs the pharmacists first[7], the engine of expansion was still his reading of demand rather than the science inside the company.

Dependence on Guronsan, and the missed dividend it led to

After the war, as medical demand for liver-function drugs widened, an opportunity arose to industrialise the glucuronic acid research of Professor Ishidate Morizo (石館守三) of the University of Tokyo. Chugai obtained the patent rights in 1950 and launched the detoxicant Guronsan (グロンサン) as an injectable solution in 1951. When the company moved to raise output to a tonne a month there was opposition inside the firm, but Ueno overrode it flatly: I am certain of this. But if by any chance it fails, I will put up my house and my land as collateral against the debt by way of apology[8]. In 1954 a synthesis from starch and dilute nitric acid was established, and the market widened from prescription use into over-the-counter medicine. Creating new drugs not from a laboratory of its own but by turning outside academic results into products was the prewar import-agency model transposed onto a domestic academic base — a choice that carried over, intact, the same constraints on the scale of R&D spending and on people.

Guronsan grew into the pillar of Chugai’s sales, but the depth of that single-product dependence came back as a management risk. In 1965 Tanabe Seiyaku’s later-arriving Aspara (アスパラ) was selling well while Orupa (オルパ), the product Chugai put up against it, was reported to be going nowhere — one trade journal remarked that you rather want to say sarcastically that it should have been called Orca[9]. In September 1964 the company set up the Chugai-kai (中外会) scheme to secure stable demand for its pharmacy-channel medicines[10], but excessive competition combined with a tendency among consumers to hold off buying health tonics and with the cold-remedy scandal, and sales through pharmacies fell[11]. As a result the year to March 1966 saw earnings deteriorate, Guronsan’s weak sales among the causes, and the company was driven into a missed dividend and a call for 420 voluntary early retirements[12]. That experience prompted a diversification of research and a rethink of the business portfolio: the Central Research Laboratory had been established in 1960, and in 1971 Chugai entered clinical diagnostics, beginning to widen the range of products. The all-in management that had run from Zarsobrocanon had reached its limit, and the company was forced to generate its next axis out of research of its own. The biotechnology work it would take up in the mid-1970s started from this reflection, the memory of the missed dividend becoming the resource that sustained long-term investment in an immature field.

Read the full history in Japanese →

Notes

  1. 中外製薬 有価証券報告書【沿革】 (Chugai Pharmaceutical, annual securities report, corporate history section)↩
  2. 中外製薬 有価証券報告書【沿革】 (Chugai Pharmaceutical, annual securities report, corporate history section)↩
  3. 中外製薬 有価証券報告書【沿革】 (Chugai Pharmaceutical, annual securities report, corporate history section)↩
  4. 月刊経済 (Gekkan Keizai, June 1965)↩
  5. 中外製薬 有価証券報告書【沿革】 (Chugai Pharmaceutical, annual securities report, corporate history section)↩
  6. 月刊経済 (Gekkan Keizai, June 1965)↩
  7. 月刊経済 (Gekkan Keizai, June 1965)↩
  8. ダイヤモンド (Diamond, 25 March 1963)↩
  9. 月刊経済 (Gekkan Keizai, June 1965)↩
  10. 企業の歴史 : 明治百年 (Corporate Histories: A Century of Meiji, Keizai Shunju-sha, 1968)↩
  11. 企業の歴史 : 明治百年 (Corporate Histories: A Century of Meiji, Keizai Shunju-sha, 1968)↩
  12. 企業の歴史 : 明治百年 (Corporate Histories: A Century of Meiji, Keizai Shunju-sha, 1968)↩

References & sources

  1. Chugai Pharmaceutical Co., Ltd. (annual securities reports), including the corporate-history section, and company disclosures on the Roche strategic alliance of December 2001 and the merger with Nippon Roche of October 2002.
  2. Diamond (Diamond, Inc.), 25 March 1963, on Chugai Pharmaceutical’s turn into a high-earning company.
  3. Gekkan Keizai, June 1965, on the isolation of Ueno Juzo, once the industry’s star. NDL Digital Collections.
  4. Corporate Histories: A Century of Meiji, Keizai Shunju-sha (1968), the Chugai Pharmaceutical entry.

Yen amounts are converted at the average rate of each figure’s own year — not today’s rate; revenue charts are shown in yen. Exchange rates & sources — the full ¥/US$ table →

Data API

Chugai Pharmaceutical’s history, presidents and financials are published as static JSON — no key, plain GET. One API per public page, and one per section where a page carries several tables. Full specification →

/api/4519/company.json ·/api/4519/history.json ·/api/4519/ceo.json ·/api/4519/financials.json ·/api/4519/financials/segment.json ·/api/4519/financials/pl.json ·/api/4519/financials/cf.json ·/api/4519/financials/bs.json ·/api/4519/financials/employee.json ·/api/4519/financials/stock.json ·/api/4519/financials.csv ·/api/4519/financials_history.csv

/api/companies.json ·/api/decisions.json ·/api/api-manifest.json